[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585837":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":19,"responsibleParty":80,"collaborators":82,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":99,"sex":104,"minAge":105,"maxAge":10,"enrollmentInfo":106,"targetDuration":109,"studyType":110,"phases":10,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":126,"whyStopped":10,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Universität des Saarlandes","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"European SLD Registry",null,"The EU-SLD registry comprises patients from 18 european countries and a study cohort of n=8.984 with most recent cases recruited in the prospective LITMUS cohort study. Now followed up as part of the LOVE Study in the EU-LIVERAIM project.",[13],{"name":14,"role":15,"phone":16,"phoneExt":17,"email":18},"Jörn M. Schattenberg, MD","CONTACT","+49684116","15027","gastroenterologie@uks.eu",[20,37,49,64],{"facility":21,"status":10,"city":22,"state":10,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Hôpital de la Pitié Salpêtrière","Paris","75013","France","FR",{"type":27,"coordinates":28},"Point",[29,30],2.3488,48.85341,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":35,"phoneExt":10,"email":36},"Scientific Affaires Officer, PhD, MPH","0033","j.medvedovic@ihuican.org",{"facility":38,"status":10,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":48,"contacts":10},"University Medical Center Saarland, Department of Internal Medicine II","Homburg","Saarland","66421","Germany","DE",{"type":27,"coordinates":45},[46,47],7.33867,49.32637,{"lat":47,"lon":46},{"facility":50,"status":10,"city":51,"state":10,"zip":10,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Division of Gastroenterology, Department of Medical Sciences, University of Turin","Turin","Italy","IT",{"type":27,"coordinates":55},[56,57],7.68682,45.07049,{"lat":57,"lon":56},[60],{"name":61,"role":15,"phone":62,"phoneExt":10,"email":63},"Division of Gastroenterology, Department of Medical Sciences","0039 11 6333272","elisabetta.bugianesi@unito.it",{"facility":65,"status":10,"city":66,"state":10,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Translational & Clinical Research Institute Faculty of Medical Sciences","Newcastle upon Tyne","NE2 4HH","United Kingdom","UK",{"type":27,"coordinates":71},[72,73],-1.61396,54.97328,{"lat":73,"lon":72},[76],{"name":77,"role":15,"phone":78,"phoneExt":10,"email":79},"Kristy Wonders","+44","SLD.Registry@newcastle.ac.uk",{"type":81,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[83,85,87,89,91,93,95],{"name":84,"class":6},"Universitatsmedizin Mainz - 1. Medizinische Klinik",{"name":86,"class":6},"Newcastle University",{"name":88,"class":6},"Barcelona Institute for Global Health",{"name":90,"class":6},"Odense University Hospital",{"name":92,"class":6},"Hospital Clinic of Barcelona",{"name":94,"class":6},"Assistance Publique - Hôpitaux de Paris",{"name":96,"class":6},"University of Turin, Italy","100585837","long-term-follow-up-to-determine-outcome-in-liver-disease-love-study-100585837",false,"NCT06907563","Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)","LOVE","Inclusion Criteria:\n\n* Previous Informed consent for cohort studies\n* \\> 18 years of age\n* Diagnosis of SLD (MASLD, MetALD, ALD)\n\nExclusion Criteria:\n\n* No consent for previous cohort studies\n* \\\u003C 18 years of age\n* No Diagnosis of SLD (MASLD, MetALD, ALD)","ALL","18 Years",{"count":107,"type":108},30000,"ESTIMATED","10 Years","OBSERVATIONAL","The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.",[113,114,115,116],"Steatotic Liver Disease","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","Steatotic Liver Disease of Mixed Origin (MetALD)","ALD - Alcoholic Liver Disease",[118,119,120,121,122,123,124,125],"MASH","SLD","NITs","MASLD","ALD","MetALD","Metabolism","Liver","NOT_YET_RECRUITING","2025-03-26",{"date":129,"type":130},"2025-04-02","ACTUAL",{"date":132,"type":108},"2025-04-15",{"date":134,"type":108},"2035-12-31",{"name":5,"class":6},4]